PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation

Clinical Cancer Research (2016) - Comments
pubmed: 27178741 doi: 10.1158/1078-0432.ccr-15-2724 issn: 1078-0432 issn: 1557-3265

De-Wei Wu, Tzu-Chin Wu, Chih-Yi Chen, Huei Lee